Renal and Cardiovascular Effects of Terlipressin in Patients With Cirrhosis and Ascites

The purpose of this study is to investigate the effect of terlipressin on myocardial perfusion and renal function.

Hypothesis: Significant improvement of renal function reflected by: glomerular filtration rate (GFR), renal blood flow (RBF), excretion of salt and metabolites in the urine and related hormones and peptides in the blood. No effect on the systolic function of the heart.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cirrhosis Ascites Fibrosis Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Hvidovre Hospital

Copenhagen, Hvidovre, 2650, Denmark

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Cirrhosis and ascites

Treatment and study plan

Terlipressin

Drug

Sponsors and collaborators

Lead sponsor

Hvidovre University Hospital

Other

Registry information

Important dates

Study start: 2004
Study completion: 2006
First posted: Jun 27, 2005
Registry last updated: Mar 9, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed